Covidien plc: All Recent News

• All recent news
• Earnings news

Healthy Monday for Healthcare 11/23/2009

With a finish line in the massive healthcare reform race in sight, and some upgrades in the sector on Monday morning, stocks in the healthcare sector are surging. At TheStreet.com

Amazon: Analysts' Upgrades, Downgrades 11/23/2009

See who made what calls. At TheStreet.com

Covidien says FDA extends Exalgo review 11/20/2009

NEW YORK (AP) - Health care company Covidien PLC said Friday the Food and Drug Administration will take longer than expected to review the potential opioid pain drug Exalgo. Associated Press

UPDATE 1-Covidien says FDA extends review of opiod pain drug 11/20/2009

... At Thomson Reuters

FDA Extends Review of NDA for Exalgo™ 11/20/2009

Covidien (NYSE:COV), a leading global provider of healthcare products, today announced that the U.S. Food and Drug Administration (FDA) has set a new action date under the Prescription Drug User Fee... Business Wire

Market Report -- In Play (COV) 11/20/2009

Covidien announces that FDA Extends Review of NDA for Exalgo Co announces that the FDA has set a new action date under the Prescription Drug User Fee Act for the review of the New Drug Application for... Briefing.com

RIM: Analysts' Upgrades, Downgrades 11/18/2009

See who made what calls. At TheStreet.com

UPDATE 2-Covidien raises 2010 sales outlook, shares rise 11/17/2009

... At Thomson Reuters

UPDATE 2-Covidien raises 2010 sales outlook, shares rise 11/17/2009

... At Thomson Reuters

Covidien Rises on Improved '10 View 11/17/2009

... At Barron's

Home Depot, Target: Tuesday's Headlines 11/17/2009

Tuesday's early headlines include earnings frmo Home Depot and Target. At TheStreet.com

Covidien raises fiscal 2010 revenue growth outlook 11/17/2009

NEW YORK (AP) - Drug and medical device maker Covidien PLC raised its fiscal 2010 revenue forecast Tuesday, expecting stronger sales of medical devices and pharmaceuticals. Associated Press

Covidien 4Q profit down 86 pct. as expenses rise 11/17/2009

NEW YORK (AP) - Drug and medical device maker Covidien PLC said Tuesday its profit dropped 86 percent in its fiscal fourth quarter due to increased sales and marketing costs, as well as one-time charges. Associated Press

Covidien quarterly net income drops 86% 11/17/2009

LONDON (MarketWatch) -- Covidien said fourth-quarter net income dropped to $56 million, or 11 cents a share, from $409 million, or 81 cents a share, a year ago. On an adjusted basis, earnings per share at the healthcare products firm totaled 72 cents. Analysts had been expecting earnings of 70 cents a share. Sales were virtually flat at $2.7 billion, hit by unfavorable exchange rate moves. The firm upped its fiscal 2010 sales guidance to reflect the recent weakening of the U.S. dollar, the acquisition of Aspect Medical Systems and FDA approvals of Oral Transmucosal Fentanyl Citrate and... At MarketWatch

Market Report -- In Play (COV) 11/17/2009

Covidien beats by $0.02, beats on revs; issues upside FY10 revenue guidance Reports Q4 (Sep) earnings of $0.72 per share, excluding non-recurring items, $0.02 better... Briefing.com

More News

Market Report

News by Symbol

Today's Investing Articles

Breaking News

News by Topic

News by Industry

MSNBC News

MSN Money

Search MSN Money

Message Boards

Site Status